Celgene, Acceleron Say Trial on Blood-Disorder Drug Yields Positive Results -- Update
July 09 2018 - 5:36PM
Dow Jones News
By Nishant Mohan and Stephen Nakrosis
Celgene Corp. (CELG) and Acceleron Pharma Inc. (XLRN) reported
positive results from a trial of their drug Luspatercept, a drug to
treat chronic anemia, beta-thalassemia and myelofibrosis.
The results announced Monday, the companies said, reflect
testing on beta-thalassemia patients who are dependent on blood
transfusions. Patients showed at least a one-third reduction in
dependence on transfusions, the companies said.
The companies also said "the drug achieved primary and all key
secondary endpoints in phase III 'BELIEVE' study in adults with
transfusion-dependent beta-thalassemia and all key secondary
endpoints in phase III 'BELIEVE' study in adults with
transfusion-dependent beta-thalassemia."
The companies plan to submit regulatory applications for
Luspatercept in the U.S. and Europe in the first half of 2019.
Shares of Celgene were up 0.8%, to $84.55, in after-hours
trading Monday after closing at $83.85. Shares of Acceleron closed
at $47.40 and were up 11%, to $52.50, after hours.
Write to Nishant Mohan at nishant.mohan@wsj.com and Stephen
Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
July 09, 2018 18:21 ET (22:21 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Apr 2023 to Apr 2024
Real-Time news about Celgene Corporation (NASDAQ): 0 recent articles
More Celgene Corp. News Articles